Synaptogenix, Inc. (SNPX)
NASDAQ: SNPX · Real-Time Price · USD
2.432
+0.012 (0.51%)
At close: Apr 1, 2025, 4:00 PM
2.562
+0.130 (5.34%)
After-hours: Apr 1, 2025, 4:04 PM EDT
Company Description
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company.
It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury.
The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.
The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Alan Tuchman |
Contact Details
Address: 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 United States | |
| Phone | 973 242 0005 |
| Website | synaptogen.com |
Stock Details
| Ticker Symbol | SNPX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001571934 |
| CUSIP Number | 87167T201 |
| ISIN Number | US87167T2015 |
| Employer ID | 46-1585656 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alan J. Tuchman M.D., MBA(FAAN) | Chief Executive Officer and Director |
| Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer and Director |
| Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 5, 2024 | ARS | Filing |
| Oct 28, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 21, 2024 | EFFECT | Notice of Effectiveness |
| Oct 16, 2024 | UPLOAD | Filing |